Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dithranol + tazarotene
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
Dithranol + tazarotene is a combination topical treatment for psoriasis. This combination therapy has been shown to significantly increase the antipsoriatic effectiveness compared to dithranol monotherapy. Tazarotene, a retinoid that works by binding to retinoic acid receptors, enhances the efficacy of dithranol, which is a traditional antipsoriatic agent. Clinical studies have demonstrated that this combination leads to faster healing and greater reduction in Psoriasis Area and Severity Index (PASI) scores, though it may cause increased skin irritation.
02
Targets
RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on dithranol + tazarotene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dithranol + tazarotene.